Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Brain Neoplasms 1

Interventions

mogamulizumab 1cobomarsen 1Lenalidomide 1Interleukin-15 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia-Lymphoma, Adult T-Cell × Interleukin-15 × Clear all
NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡